.Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IB03_Indium111inAntiovariumca.Indium111inAntiovariumca .Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IB03_Indium111inAntiovariumca.Indium111inAntiovariumca| name: | Indium111inAntiovariumcarcinomaAntibody | |
| ATC code: | V09IB03 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 5 | mg |
| volume of distribution: | 4.5 | L |
| clearance: | 0.01 | L/hr |
| other parameters in model implementation | ||
Indium (111In) antiovariumcarcinoma antibody is a radiopharmaceutical consisting of an antibody against human ovarian carcinoma cells, labeled with radioactive indium-111. It is used as a diagnostic imaging agent to localize ovarian carcinoma metastases or recurrences. It is not currently approved for routine clinical use, primarily used experimentally or in investigational settings.
No specific published pharmacokinetic parameters found in the literature for indium (111In) antiovariumcarcinoma antibody in humans. General estimates are reported for radiolabeled monoclonal antibodies in adult cancer patients.
Macklis, RM, et al., & Burakoff, SJ (1988). Biodistribution studies of anti-Thy 1.2 IgM immunoconjugates: implications for radioimmunotherapy. International journal of radiation oncology, biology, physics 15(2) 383–389. DOI:10.1016/s0360-3016(98)90020-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/3403319